AVITA Medical (RCEL) Projected to Post Earnings on Thursday

AVITA Medical (NASDAQ:RCEL) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

AVITA Medical (NASDAQ:RCEL) last released its quarterly earnings data on Thursday, February 13th. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). The company had revenue of $18.41 million for the quarter, compared to analyst estimates of $18.40 million. AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AVITA Medical Stock Down 3.5 %

NASDAQ RCEL opened at $9.41 on Tuesday. AVITA Medical has a 1-year low of $7.51 and a 1-year high of $18.93. The stock’s 50 day moving average is $10.34 and its two-hundred day moving average is $10.68. The company has a current ratio of 2.83, a quick ratio of 2.47 and a debt-to-equity ratio of 9.39. The company has a market capitalization of $246.71 million, a price-to-earnings ratio of -3.94 and a beta of 1.55.

Analysts Set New Price Targets

A number of research firms have recently issued reports on RCEL. D. Boral Capital cut their target price on shares of AVITA Medical from $25.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Lake Street Capital cut their target price on shares of AVITA Medical from $20.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of AVITA Medical in a research note on Tuesday, December 24th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $12.00 target price (up previously from $9.00) on shares of AVITA Medical in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Insider Buying and Selling at AVITA Medical

In other AVITA Medical news, Director Robert Mcnamara bought 10,000 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was bought at an average price of $10.09 per share, for a total transaction of $100,900.00. Following the transaction, the director now owns 45,749 shares of the company’s stock, valued at approximately $461,607.41. The trade was a 27.97 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders acquired 12,461 shares of company stock worth $129,689. Insiders own 1.82% of the company’s stock.

About AVITA Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.